EGI
CORT icon

EAM Global Investors’s Corcept Therapeutics CORT Stock Holding History

EAM Global Investors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-59,167
Closed -$4.34M – 24
2025
Q2 		$4.34M Sell
59,167
-15,789
-21% -$1.14M 1.13% 60
2025
Q1 		$8.56M Buy
+74,956
New +$4.56M 2.33% 4
2022
Q4 		– Sell
-81,268
Closed -$2.08M – 189
2022
Q3 		$2.08M Buy
+81,268
New +$2.17M 0.55% 59

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EAM Global Investors's CORT Position: Q3 2025 in Review

EAM Global Investors sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 59,167 shares — an estimated $4.34M sold.

EAM Global Investors first reported a position in CORT in Q3 2022 and held it in 3 quarters. The position peaked at $8.56M in Q1 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • EAM Global Investors reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • EAM Global Investors sold 59,167 Corcept Therapeutics shares in Q3 2025, an estimated $4.34M.
  • EAM Global Investors first reported a position in Corcept Therapeutics in Q3 2022 and held it in 3 quarters.
  • EAM Global Investors's Corcept Therapeutics position peaked at $8.56M in Q1 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on EAM Global Investors's 13F filing for Q3 2025, filed 14 Nov 2025.